Chicago, IL, June 2020 -- An artificial intelligence (AI)-based breast ultrasound software from Koios Medical, Inc. proven to significantly enhance the accuracy and consistency of lesion assessment for physicians across a wide range of experience levels, per a study recently published in the American Journal of Roentgenology, is now being used to diagnose breast cancer earlier for patients with appointments cancelled due to Covid-19.
Several community practices and major academic medical centers primarily in the Northeast and Midwest have adopted this first of its kind, FDA-cleared software recognizing that prior breast ultrasound images of patients whose appointments were postponed due to Covid-19 can be analyzed using the software uncovering previously missed cancers. High-risk patients can be immediately prioritized for biopsy and treatment if confirmed. Patients and providers benefit from this proactive approach taken by physicians during the Covid-19 induced slowdown that also postpones lower risk patient appointments. Up to 40% of patients scheduled for follow-up may safely defer follow-up an additional six to twelve months.
Covid-19 presented clinicians with the unique challenge of addressing patient risk while unable to attend to the specific needs of each patient while “sheltering at home”. Physicians, technologists, and office staff must also take additional precautions to mitigate the risk of exposure when patients are seeking care. Koios DS AI software for early breast cancer detection can be used to analyze recent exams without requiring any additional appointments. Patients determined to have extremely low-risk exam findings can be rescheduled and deprioritized meaning fewer patient interactions and increased safety for physicians and staff.
Ad Statistics
Times Displayed: 20910
Times Visited: 407 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
“We’ve always known Koios DS Breast is a valuable weapon in the fight against breast cancer” says Chad McClennan, President & CEO, “but we really had no idea it could be such an effective tool when faced with a global pandemic. Catching cancers in patients sheltered at home while protecting doctors, nurses, technologists and office staff from avoidable exposure is an unanticipated impact that has been extremely motivating to our entire team during these challenging times.”
Until effective vaccines or treatments for Covid-19 are widely available, patients are likely to continue wanting to avoid medical facilities, particularly if earlier examinations found lesions to be low-risk.
